Blood marker may predict COVID-19 survival
NCT ID NCT05413824
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examined whether a blood test parameter called NEU-SFL, which reflects neutrophil activation, could predict the risk of death in patients hospitalized for COVID-19 in 2021. Researchers compared NEU-SFL levels between those who survived and those who died. The goal was to see if this routine lab value could help doctors identify high-risk patients early.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Nimes
Nîmes, 30029, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?